During the last session, Bluebird bio Inc (NASDAQ:BLUE)’s traded shares were 0.42 million, with the beta value of the company hitting 0.22. At the end of the trading day, the stock’s price was $3.50, reflecting an intraday loss of -5.66% or -$0.21. The 52-week high for the BLUE share is $28.60, that puts it down -717.14 from that peak though still a striking -1.71% loss since the share price plummeted to a 52-week low of $3.56. The company’s market capitalization is $34.26M, and the average trade volume was 407.86K shares over the past three months.
Bluebird bio Inc (BLUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.80. BLUE has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.42.
Bluebird bio Inc (NASDAQ:BLUE) trade information
Bluebird bio Inc (BLUE) registered a -5.66% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.66% in intraday trading to $3.50, hitting a weekly high. The stock’s 5-day price performance is -11.39%, and it has moved by -27.84% in 30 days. Based on these gigs, the overall price performance for the year is -82.67%.
The consensus price target of analysts on Wall Street is $12.5, which implies an increase of 72.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $25 respectively. As a result, BLUE is trading at a discount of -614.29% off the target high and -42.86% off the low.
Bluebird bio Inc (BLUE) estimates and forecasts
In the rating firms’ projections, revenue will increase 302.39% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 39.03M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 72.27M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 18.57M and 16.1M respectively. In this case, analysts expect current quarter sales to grow by 110.17% and then jump by 348.86% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.66%. While earnings are projected to return 71.57% in 2025, the next five years will return 67.42% per annum.
BLUE Dividends
Bluebird bio Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 10.3 million shares, is of VANGUARD GROUP INC’s that is approximately 0.2659% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $10.14 million.
Also, the Mutual Funds coming in first place with the largest holdings of Bluebird bio Inc (BLUE) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 293.12 shares. This amounts to just over 2.99 percent of the company’s overall shares, with a $1.03 million market value. The same data shows that the other fund manager holds slightly less at 256.98, or about 2.62% of the stock, which is worth about $0.9 million.
